- Home
- GLPG vs BMEZ Comparison
GLPG vs BMEZ Comparison
Compare GLPG & BMEZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- BMEZ
- Stock Information
- Founded
- GLPG 1999
- BMEZ N/A
- Country
- GLPG Belgium
- BMEZ United States
- Employees
- GLPG N/A
- BMEZ N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- BMEZ Trusts Except Educational Religious and Charitable
- Sector
- GLPG Health Care
- BMEZ Finance
- Exchange
- GLPG Nasdaq
- BMEZ Nasdaq
- Market Cap
- GLPG 1.8B
- BMEZ 1.5B
- IPO Year
- GLPG 2005
- BMEZ N/A
- Fundamental
- Price
- GLPG $26.86
- BMEZ $14.09
- Analyst Decision
- GLPG Sell
- BMEZ
- Analyst Count
- GLPG 4
- BMEZ 0
- Target Price
- GLPG $25.33
- BMEZ N/A
- AVG Volume (30 Days)
- GLPG 419.6K
- BMEZ 391.3K
- Earning Date
- GLPG 04-23-2025
- BMEZ 01-01-0001
- Dividend Yield
- GLPG N/A
- BMEZ 8.71%
- EPS Growth
- GLPG N/A
- BMEZ N/A
- EPS
- GLPG N/A
- BMEZ 0.54
- Revenue
- GLPG $311,493,731.00
- BMEZ N/A
- Revenue This Year
- GLPG $0.08
- BMEZ N/A
- Revenue Next Year
- GLPG $0.23
- BMEZ N/A
- P/E Ratio
- GLPG N/A
- BMEZ $30.17
- Revenue Growth
- GLPG 18.32
- BMEZ N/A
- 52 Week Low
- GLPG $22.36
- BMEZ $12.93
- 52 Week High
- GLPG $31.23
- BMEZ $16.95
- Technical
- Relative Strength Index (RSI)
- GLPG 67.75
- BMEZ 47.04
- Support Level
- GLPG $24.31
- BMEZ $13.40
- Resistance Level
- GLPG $24.91
- BMEZ $14.20
- Average True Range (ATR)
- GLPG 0.82
- BMEZ 0.49
- MACD
- GLPG 0.34
- BMEZ 0.07
- Stochastic Oscillator
- GLPG 97.49
- BMEZ 90.66
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
About BMEZ BlackRock Health Sciences Term Trust of Beneficial Interest
BlackRock Health Sciences Trust II is a closed-ended management investment company. The investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.